Conviction
1 → 3
Conviction●●●○○3 of 5
Research target$230.19Snapshot target
Thesis statusINTACTLast reviewed 7/8/26
Market cap28.55BSnapshot value
Research history
See all ILMN changes ↗What changed
Target
— → $230.19
Thesis status
NEEDS_MORE_DATA → INTACT
Last reviewed
Not reviewed → 7/8/26
Target
— → $230.19
Sequencing razor-blade: sell the sequencer (NovaSeq X, now ~90% of research volume), monetize consumables forever. BIOSECURE tailwind reshoring demand to Western platforms.
BIOSECURE OMB list (~Dec 2026) reshoring Chinese sequencing share; clinical sequencing shift (MRD, early detection, companion Dx); NovaSeq X Constellation bringing WGS to existing install base.
Roche Axelios/SBX launched July 2026 — first credible high-throughput threat in years; consumables pricing pressure (volume discounts); Ultima/Element ramping; Illumina-Grail unwind distraction.
needs X/Reddit sentiment sweep
Snapshot · 7/8/26🔴 Caution · ins-$70.5M · 13F 11+/13- · short↓0.28
Snapshot · 7/8/26